Research ExplorerPublicationsTIMP-1 and VEGF-165 serum concentration during first-line th...

TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.

Standard

TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients. / Mahner, Sven; Wölber, Linn; Zu Eulenburg, Christine Gräfin; Schwarz, Jörg; Carney, Walter; Jänicke, Fritz; Milde-Langosch, Karin; Müller, Volkmar.

In: BMC CANCER, Vol. 10, 2010, p. 139.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Mahner, S, Wölber, L, Zu Eulenburg, CG, Schwarz, J, Carney, W, Jänicke, F, Milde-Langosch, K & Müller, V 2010, 'TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.', BMC CANCER, vol. 10, pp. 139. https://doi.org/10.1186/1471-2407-10-139

APA

Mahner, S., Wölber, L., Zu Eulenburg, C. G., Schwarz, J., Carney, W., Jänicke, F., Milde-Langosch, K., & Müller, V. (2010). TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients. BMC CANCER, 10, 139. https://doi.org/10.1186/1471-2407-10-139

Vancouver

Mahner S, Wölber L, Zu Eulenburg CG, Schwarz J, Carney W, Jänicke F et al. TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients. BMC CANCER. 2010;10:139. https://doi.org/10.1186/1471-2407-10-139

Bibtex

@article{e713ac8f06fa4f73b69590241b150679,
title = "TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.",
abstract = "Angiogenesis appears to play an important role in ovarian cancer. Vascular endothelial growth factor (VEGF) has recently been implicated as a therapeutic target in ovarian cancer. The tissue inhibitor of metalloproteinase 1 (TIMP-1) is involved in tissue invasion and angiogenesis. The application of serum TIMP-1 and VEGF to monitor primary therapy and predict clinical outcome of patients with ovarian cancer is unclear.",
author = "Sven Mahner and Linn W{\"o}lber and {Zu Eulenburg}, {Christine Gr{\"a}fin} and J{\"o}rg Schwarz and Walter Carney and Fritz J{\"a}nicke and Karin Milde-Langosch and Volkmar M{\"u}ller",
year = "2010",
doi = "10.1186/1471-2407-10-139",
language = "Deutsch",
volume = "10",
pages = "139",
journal = "BMC CANCER",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.

AU - Mahner, Sven

AU - Wölber, Linn

AU - Zu Eulenburg, Christine Gräfin

AU - Schwarz, Jörg

AU - Carney, Walter

AU - Jänicke, Fritz

AU - Milde-Langosch, Karin

AU - Müller, Volkmar

PY - 2010

Y1 - 2010

N2 - Angiogenesis appears to play an important role in ovarian cancer. Vascular endothelial growth factor (VEGF) has recently been implicated as a therapeutic target in ovarian cancer. The tissue inhibitor of metalloproteinase 1 (TIMP-1) is involved in tissue invasion and angiogenesis. The application of serum TIMP-1 and VEGF to monitor primary therapy and predict clinical outcome of patients with ovarian cancer is unclear.

AB - Angiogenesis appears to play an important role in ovarian cancer. Vascular endothelial growth factor (VEGF) has recently been implicated as a therapeutic target in ovarian cancer. The tissue inhibitor of metalloproteinase 1 (TIMP-1) is involved in tissue invasion and angiogenesis. The application of serum TIMP-1 and VEGF to monitor primary therapy and predict clinical outcome of patients with ovarian cancer is unclear.

U2 - 10.1186/1471-2407-10-139

DO - 10.1186/1471-2407-10-139

M3 - SCORING: Zeitschriftenaufsatz

VL - 10

SP - 139

JO - BMC CANCER

JF - BMC CANCER

SN - 1471-2407

ER -